<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007224</url>
  </required_header>
  <id_info>
    <org_study_id>CORDUS</org_study_id>
    <nct_id>NCT04007224</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder</brief_title>
  <official_title>Comparison of Umbilical Cord Blood vs Personalized Treatment for Improving Autistic Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundatia Bio-Forum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spitalul Angiomedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundatia Bio-Forum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study evaluates in an open-label, crossover design the comparative efficacy and&#xD;
      safety of intranasal oxytocin and autologous umbilical cord blood for improving the&#xD;
      functioning of children with autistic spectrum disorder&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children aged 3-7 years diagnosed with autistic spectrum disorder and who did not previously&#xD;
      receive oxytocin or umbilical cord blood treatments, will be enrolled to receive both&#xD;
      treatments in random order. Assessment of functioning impairment will be done with&#xD;
      QCHAT/M-CHAT/CAST questionnaires initially, at 2 months, 6 months and 1 year after first&#xD;
      treatments. Either oxytocin or cord blood will be administered initially and at visit 2,&#xD;
      which will take place at 2 months. All children will receive both treatments. A total of&#xD;
      25-40 children are expected to enroll and complete the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in behaviour, interaction with family and peers</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in scores on M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire; total score, maximum 20, lower is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in behavior and social interaction</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in score on Q-CHAT (Quantitative Checklist for Autism in Toddlers) questionnaire; total score, maximum 100, lower is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in overall functioning of the child</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in score on CAST (The Childhood Autistic Spectrum Test) questionnaire; Total score, maximum 39, lower is better</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autistic Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal Oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of autologous umbilical cord blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal oxytocin</intervention_name>
    <description>daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>non-invasive treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous umbilical cord blood</intervention_name>
    <description>patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth</description>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
    <other_name>invasive treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of autistic spectrum disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metabolic or genetic disorder (ex storage disease, Down, etc),&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felician Stancioiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundatia Bio-Forum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felician Stancioiu</last_name>
    <phone>+40727500402</phone>
    <email>felicians11@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Spitalul Angiomedica</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>040245</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medicover Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raluca Bogdan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Radu Dumitrescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raluca Bogdan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponderas Academic Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Dulugiac, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laura Ion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihaela Agache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>https://bio-forum.net/clinical-trials</url>
    <description>short info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04007224/Prot_SAP_ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

